Latest Earnings Results: Q2 '26
Estimated EPS
-$0.27
Reported EPS
-$0.14
Surprise
+48.15%
Estimated Rev
$0.32M
Reported Rev
$0.35M
Surprise
+6.77%
• Reported GAAP EPS of -$0.14 up 72.00% YoY • Reported revenue of $0.35M down -60.75% YoY • Evogene expects full-year 2026 cash usage to be approximately $8.5 million to $9.5 million, compared with approximately $14.4 million in 2025 and approximately $20.5 million in 2024, with further reductions targeted.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.27 | -- | -- | N/A |
Q2 '26 | -$0.27 | -$0.14 | 48.15% | BEAT |
Q1 '26 | -$0.27 | -$0.60 | -122.22% | MISSED |
Q4 '25 | -$0.26 | -$0.61 | -134.21% | MISSED |
Q3 '25 | -$0.41 | $0.44 | 208.40% | BEAT |